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the public is seeking high-quality care. Greater in-
tegration of services is essential to addressing the
issue of quality. In the physician-assistant commu-
nity, we call it team practice. The health care system
long ago moved beyond the model of the solo prac-
titioner as the ideal way to deliver health care. Today,
all practitioners, including physicians, are integrat-
ed through an intricate network of referrals, review
systems, and shared information systems.
The question of whether greater use of nonphy-
sicians results in a growing coordination or frag-
mentation of care can be answered by studying the
team practice of physicians and physician assistants.
It is increasingly necessary that we evaluate the role,
function, and effects of team practice, rather than
focus on the contributions of individual clinicians
who are presumably acting alone.
The article by Druss et al. answers the question
of who provides health care. Research is still needed
to answer the question of how medical care, provid-
ed by a team of clinicians under the leadership of
a physician, is coordinated in actual practice and
how society can use this method to ensure appropri-
ate access to high-quality care.
 
Stephen C. Crane, Ph.D., M.P.H.
 
American Academy of Physician Assistants
Alexandria, VA 22314-1552
 
1.
 
Druss BG, Marcus SC, Olfson M, Tanielian T, Pincus HA. Trends
in care by nonphysician clinicians in the United States. N Engl J Med
2003;348:130-7.
 
dr. druss replies: 
 
I appreciate both the content and
the spirit of Dr. Crane’s letter. I agree that the study
points to a need for a better understanding of how
medical care is and, more important, should be co-
ordinated among the many groups of clinicians that
provide it. It is essential that these efforts them-
selves be both multidisciplinary and collaborative.
 
Benjamin Druss, M.D., M.P.H.
 
Emory University
Atlanta, GA 30322
bdruss@sph.emory.edu
 
Population Screening
 
to the editor: 
 
In their review article, Khoury et al.
(Jan. 2 issue)
 
1
 
 suggest that homocystinuria should
be screened for by Guthrie bacterial inhibition as-
say and treated with vitamin B
 
12
 
 and methionine
restriction. Homocystinuria occurs in several condi-
tions, including cystathionine 
 
b
 
-synthase deficien-
cy and genetic disorders of homocysteine remeth-
ylation.
 
2,3
 
 Plasma total homocysteine levels may
also be elevated because of folate deficiency or vi-
tamin B
 
12
 
  deficiency.
 
2
 
 The Guthrie test, designed
to detect hypermethioninemia, fails to detect ab-
normalities of homocysteine remethylation. Hyper-
methioninemia occurs not only in cystathionine
 
b
 
-synthase deficiency but also in a variety of other
conditions.
 
2,4,5
 
 Cystathionine 
 
b
 
-synthase deficien-
cy is readily differentiated from other disorders,
since either plasma cystathionine will not be detect-
ed at all or the level will be very low in patients with
this deficiency, whereas the level will be normal or
elevated in patients with other conditions causing
elevated methionine or total homocysteine levels.
 
5
 
Methionine restriction may be therapeutic in cys-
tathionine 
 
b
 
-synthase deficiency but not in the lat-
ter conditions. Patients with such a deficiency may
have a response to vitamin B
 
6
 
. Methionine restric-
tion and betaine are used in patients without a re-
sponse to vitamin B
 
6
 
. Vitamin B
 
12
 
 and folate are
sometimes used as adjuvant therapy.
 
2
 
 Vitamin B
 
12
 
is specifically indicated for disorders affecting meth-
ylcobalamin synthesis.3 Diagnosis and treatment of
cystathionine b-synthase deficiency and errors af-
fecting the homocysteine remethylation may prevent
mental retardation and thromboembolic episodes.
We recommend that disorders of methionine and
homocysteine metabolism be classified according
to the specific causative deficiency of enzyme activity
or vitamin and that concurrent assays of plasma to-
tal homocysteine, cystathionine, and methionine be
performed. Methylmalonate should be measured if
disorders related to cobalamin are suspected. Assays
of plasma S-adenosylmethionine and sarcosine can
be performed for the rarer inborn errors.
Sally P. Stabler, M.D.
University of Colorado Health Sciences Center
Denver, CO 80262
sally.stabler@uchsc.edu
S. Harvey Mudd, M.D.
National Institute of Mental Health
Bethesda, MD 20892
Editor’s note: The University of Colorado and Dr. Sta-
bler hold patents on the use of homocysteine, cysta-
thionine, and methylmalonic acid in the diagnosis
of folate deficiency and vitamin B12 deficiency.
A company has been formed at the University of
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Colorado to perform the assays. Dr. Stabler holds
patents on combination vitamin treatment of ho-
mocysteine.
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to the editor: The article by Khoury et al. missed
several important points. The first principle set forth
by Wilson and Jungner1 mandates that screening
should be undertaken only for health problems that
are important in terms of both the severity of dis-
ease and its frequency at the level of public health.
Most monogenic disorders do not qualify in terms
of frequency.
Fear of disease by laypersons, a defensive med-
icolegal culture, and a weakly regulated market-
place mean that purveyors of “at risk” testing will
proliferate, resulting in unforeseen social and psy-
chological harms. Once genetic variants are identi-
fied, what then?
Correctly recognizing that tandem mass spec-
trometry identifies many conditions for which no
treatment, clear understanding of appropriate man-
agement, or preventive strategies exists, the authors
justify this technique on the basis that it can help
to eliminate the need for “diagnostic odysseys” if
low-probability health problems emerge. They fail
to mention that tandem mass spectrometry and sim-
ilar methods for mass genetic screening almost
guarantee an epidemic of therapeutic odysseys, as
anxious parents seek multiple treatments for diseas-
es that may never become symptomatic. We should
not allow the potential hazards and costs of genetic
screening to remain as underemphasized as they
were in the article by Khoury et al.
Richard Fielding, Ph.D.
Wendy Lam, Ph.D.
Gabriel M. Leung, Ph.D.
University of Hong Kong
Hong Kong, China
fielding@hkusua.hku.hk
1. Wilson JMG, Jungner G. Principles and practice of screening for
disease. Public Health Pap 1968;34:11-163.
the authors reply: We agree with Stabler and
Mudd that the screening of newborns for hyper-
methioninemia will identify only a subgroup of
patients with homocystinuria and will identify pa-
tients who have hypermethioninemia for other
reasons, including liver disease. The challenge for
those desiring more comprehensive ascertainment
of inborn errors of metabolism is to develop tech-
nological approaches that will be able to accom-
modate high sample throughput in a cost-effective
manner.1,2 The application of tandem mass spec-
trometry to the screening of newborns offers detec-
tion to a much larger group of infants with specif-
ic inborn errors of metabolism than was previously
possible.
Fielding et al. raise important issues regard-
ing the selection of diseases for population-based
screening. All 50 states and the District of Colum-
bia have determined that newborn screening pro-
grams represent an important investment for the
prevention of death and disability.3 These are deci-
sions that must be made openly, with full represen-
tation of professionals and the public. The costs of
investment in new technologies such as tandem
mass spectrometry must be considered carefully.
Population screening requires assessment of
the goals for the program and ongoing evaluation
to ensure that its goals are being achieved. We ap-
preciate the opportunity to expand the dialogue
about screening.
Muin J. Khoury, M.D., Ph.D.
Centers for Disease Control and Prevention
Atlanta, GA 30333
Linda L. McCabe, Ph.D.
Edward R.B. McCabe, M.D., Ph.D.
David Geffen School of Medicine at UCLA
Los Angeles, CA 90095-1752
emccabe@mednet.ucla.edu
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